Molecular Insight's Azedra enters Phase II clinical trials

08/9/2009 | Mass High Tech (Boston)

Molecular-imaging and radiotherapy firm Molecular Insight Pharmaceuticals started Phase II clinical trials for Azedra, an investigational treatment for malignant relapsed/refractory pheochromocytoma. If approved, the drug will be the first pheochromocytoma treatment in the U.S., the company said. Molecular Insight also plans to explore the drug for pediatric neuroblastoma.

View Full Article in:

Mass High Tech (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ